How Tubulis ADCs Target Tumors

Dominik Schumacher, CEO and co-founder of Tubulis GmbH, joins Venrock's Nimish Shah to dive deeper on the company's ADC technology which specifically targets cancer cells thereby reducing side effects on the rest of the body, dramatically improving outcomes and quality of life for patients. They cover how their chemistry sets them apart from similar ADC treatments, what other diseases their breakthrough can target, and how staying data-driven helped him seamlessly move from the lab to leadership.